Dr. Christine Lemke (Chairperson)
Christine Lemke serves as Head of Global Corporate Development at Ferring. She is an international executive with 20+ years of increasing responsibility in corporate and business development, R&D, operations as well as financial management in the pharmaceutical, medical device and biotech industry. Prior to joining Ferring in 2020, she worked for Shire as Head of R&D Strategy and Planning and for Bayer as VP Strategy (Corporate and Pharmaceutical) and Head of R&D Department at Business Consulting, Bayer’s in-house management consultancy.
Christine Lemke holds a DVM from the FU Berlin, Germany, a Dr. vet. med. of the School of Veterinary Medicine Hannover, Germany and an MBA from the University of Denver, Colorado, USA.
Dr. Frank Kalkbrenner
Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim (BI) Venture Fund, the lead investor in Acousia. He has extensive experience in Drug Discovery and Development as well as in licensing and business development. Before joining the venture fund in 2010 Frank Kalkbrenner headed the German licensing organization of BI.
Frank Kalkbrenner received his MD from the University of Berlin and did his post-doc research at the Max-Planck-Institute in Berlin before he trained in Pharmacology and Toxicology. Before moving to licensing he held several position in Research in Inflammatory and Pulmonary diseases at Schering AG and BI.
Prof. Dr. Hubert Löwenheim
Hubert Löwenheim is Medical Director of the ENT University Clinic in Tübingen and Principal Investigator of “Regenerative Biology Group”. He has extensive experience in the field of regenerative hearing loss therapies both scientifically and clinically. He was the first describing the involvement of cell cycle regulators esp. p27Kip1 in the proliferation and differentiation of hair cells and supporting cells in the cochlea. In 1998, based on these discoveries he co-founded the company Otogene AG in Tübingen and its subsidiary Otogene Inc. in Seattle with the aim to identify an inhibitor of p27Kip1 as regenerative drug.
Hubert Löwenheim received his MD from Goethe University, Frankfurt am Main and trained in Otorhinolaryngology at the University of Tübingen. His doctoral degree from Goethe University is in auditory physiology, his Habilitation degree from Tübingen University is in auditory regenerative biology. His clinical focus is in Otology & Neurootology. He has published over 50 scientific articles in the area of hearing research.
Dr. Harald Poth
Harald Poth is Senior Investment Manager at LBBW Venture Capital GmbH in Stuttgart and heads the Life Science Team with now 19 years investment experience. Currently, he is chairman of the board of Phenex Pharmaceuticals AG, amcure GmbH and biametrics GmbH. Prior to his VC activities he headed the Life Science startup agency in Baden-Württemberg.
Harald Poth studied Biology at the University Hohenheim in Stuttgart and holds a PhD with distinction in Microbiology from Hohenheim. He gained international scientific experience at the Université de Genève and the University of Pennsylvania School of Medicine in Philadelphia and the Biotechnology Research Centre in Braunschweig.
Thomas Hoffmann is co-founder and CFO of Phenex Pharmaceuticals AG. He has 20 years working experience in the biotechnology industry and was involved in that time in numerous transactions including major licensing and asset deals, trade sales, financing rounds and public offerings.
Thomas Hoffmann studied business administration and economy and holds a Dipl.-Kaufmann degree from the University of Mannheim.